Information about Sibutramine
Sibutramine is a serotonin and norepinephrine reuptake inhibitor which has been used for short- and long-term therapy of obesity, but which was withdrawn from use in 2010 because of increase risk of cardiovascular events.
Liver safety of Sibutramine
In large clinical trials, sibutramine therapy was not associated with serum enzyme elevations, and it has only rarely been implicated in cases of clinically apparent, acute liver injury.
Mechanism of action of Sibutramine
Sibutramine (si bue' tra meen) is a beta-phenylethylamine that inhibits the synaptic reuptake of both serotonin and norepinephrine. Developed initially as an antidepressant, it had little effect on depression, but its use was associated with weight loss that appeared to be due to decreased appetite and reduced caloric intake.
FDA approval information for Sibutramine
Sibutramine was approved for use as therapy of obesity in the United States in 1997 and was widely prescribed until it was withdrawn in 2010 because of studies demonstrating an increased risk of myocardial infarction and stroke with its use.
Dosage and administration for Sibutramine
Sibutramine was previously available as capsules of 5, 10 and 15 mg under the trade name Meridia. The recommended dose was 10 mg once daily, with adjustment up to 15 mg daily or down to 5 mg daily based upon clinical effect and tolerance.
Side effects of Sibutramine
Common side effects included dry mouth, headache, insomnia, constipation, nausea and increased blood pressure and heart rate. While no longer available commercially, silbutramine has been found as a contaminant in in some weight loss products available over-the-counter or via the internet.